

CURRICULUM VITAE
HYERIM KANG, Ph.D.

Last updated: September 2020

CONTACT INFORMATION

Department of Pharmaceutical Outcomes and Policy
College of Pharmacy, University of Florida
1225 Center Drive HPNP Building Room 2330 Gainesville Florida 32601-0496
E-mail: h.kang@cop.ufl.edu

EDUCATION

2016. 03 – 2020.02 Doctor of Philosophy (Ph.D.)
 Pharmaceutical Policy and Outcomes Research
 School of Pharmacy, Sungkyunkwan University, Korea
2012. 03 – 2016. 02 Doctor of Pharmacy (PharmD)
 School of Pharmacy, Sungkyunkwan University, Korea
2007. 03 – 2012. 02 Undergraduate of Department of Mathematics Education
 College of Education, Ewha Womans University, Korea

DISSERTATION

Doctor of philosophy, Health and Social Pharmacy
Analyzing the risk of neuropsychiatric adverse events associated with oseltamivir using real-world data
(Supervisor: Ju-Young Shin)

LICENSURE AND CERTIFICATION

2016. 03 – Present Registered Pharmacist in South Korea

PROFESSIONAL POSITION

2020. 06 – Present Post-Doctoral Associate
 Department of Pharmaceutical Outcomes and Policy
 College of Pharmacy, University of Florida

2018. 07 – 2018. 08 Intern, Oncology Market Access, Emerging & Growth Markets
Novartis Pharma Services AG, Dubai, United Arab Emirates
- Gained understanding of healthcare system in Middle East countries
 - Conducted systematic literature research on the burden of illness of sickle cell disease in the Middle East countries and reported data gap that needs to be considered for developing a value assessment framework
 - Provided insights and experiences of Korea healthcare system for Middle East countries to benchmark to increase the efficiency
2018. 07 Intern, Oncology Market Access, Emerging & Growth Markets
Novartis Pharma AG, Basel, Switzerland
- Gained an understanding of how a pharmaceutical company works to get innovative medicines to each country
 - Participated in departmental meetings to learn the insights and gain real-life experiences
 - Obtained knowledge on the daily operations of a pharmaceutical company including compliance, finance, communications, marketing, medical, market access, healthcare systems, and supply chain.
2018. 03 – 2019. 02 Graduate Student Teaching Assistant, School of Pharmacy
Sungkyunkwan University, Korea
- Supported in the teaching and discussion of graduate students in the lecture of “Modeling for Healtheconomic Evaluation”
2016. 04 – 2017. 08 Pharmacist (Part-time), Wonkwang University’s College of Medicine Sanbon Medical Center, Korea
- Interpreted and evaluated physician prescriptions to prepare and dispense appropriate medication dosage forms for inpatient and outpatient treatment
2016. 03 – 2020. 02 Researcher, Department of Pharmaceutical Policy and Outcomes Research
School of Pharmacy, Sungkyunkwan University, Korea
2013. 07 Intern, Quality Assurance and Quality Control
Korea United Pharm. Int’l JSC, Thuan An, Vietnam
- Performed inspections on the products produced from the pharmaceutical manufacturing unit

- Assisted quality assurance by processing the documentation, establishing standards, and conducting internal audits
- Conducted collaborative research on the formulation of metformin with the University of Medicine and Pharmacy of Ho Chi Minh City

RESEARCH EXPERIENCE

2020. 07 – Present **Real-World Evidence;** A study on the assessment of the effects of extended use of apixaban or warfarin beyond 6 months of initial treatment on the risk of recurrent venous thromboembolism (VTE) among patients with a history of recurrent VTE
Funding source: BMS/Pfizer Alliance American Thrombosis Investigator Initiated Research Program
Role: Participating Researcher
- Literature review, analyzing MarketScan database to conduct a retrospective cohort study in real-world clinical care settings, and writing of manuscripts for publication
2019. 01 – 2019.12 **Real-World Evidence;** A study on the assessment of the switchability of generic products for chronic diseases: focused on hypertension, hyperlipidemia, and diabetes
Funding source: National Health Insurance Service
Role: Participating Researcher
- Designed and conducted a retrospective pharmacoepidemiologic study to assess health outcomes regarding a switch to generic medications using National Health Insurance Services database
2019. 01 – 2020.02 **Cost-Effectiveness Modeling;** Cost-effectiveness of Ribociclib for treating advanced or metastatic breast cancer
Funding source: Novartis Korea
Role: Leading Researcher
- Built a three-state partitioned survival model to estimate the cost-effectiveness of Ribociclib
 - Conducted cost-effectiveness analysis of Ribociclib
2018. 06 – 2019. 01 **Real-World Evidence;** A study on the risk of cardiovascular diseases of the patients with established cardiovascular diseases using claims data

Funding source: Sanofi-Aventis Korea

Role: Leading Researcher

- Analyzed the future risk of cardiovascular diseases among the patients with established cardiovascular diseases using Korean National Sample Cohort database

2018. 02 – 2018. 12 **Cost-of-illness analysis;** A study on the introduction of the new assessment method for innovative health technologies

Funding source: National Evidence-based Healthcare Collaborating Agency

Role: Participating Researcher

- Analyzed economic burden of patients associated with the introduction of value-based new health technology assessment

2017. 10 – 2018. 02 **Budget impact analysis;** Cost-effectiveness of Fulvestrant for treating breast cancer

Funding source: AstraZeneca Korea

Role: Participating Researcher

- Conducted the budget impact analysis of using Fulvestrant for treating breast cancer in Korea
- Applied micro-costing and gross-costing methods to estimate the costs required for cost-effectiveness analysis

2017. 08 – 2018. 09 **Pharmacoepidemiology;** A study on the risk of neuropsychiatric adverse events associated with the use of Oseltamivir

Funding source: National Research Foundation of Korea

Role: Leading Researcher

- Designed and conducted a case-crossover study to evaluate whether the use of oseltamivir triggers neuropsychiatric adverse events.

2016. 07 – 2018. 11 **Real-World Evidence;** Comparative effectiveness researches for treatment, diagnosis, and monitoring in asthma using a multi-center cohort

Funding source: Korea Health Industry Development Institute

Role: Participating Researcher

- Conducted cost-effective analysis of continuation versus discontinuation of inhaled corticosteroid treatment in mild asthma using claims data merged with the multi-center Korean asthma cohort data

- Conducted a population-based observational study on risk factors of asthma exacerbation based on asthma severity using claims data
- Analyzed the impact of asthma-COPD overlap on the incidence of depression and anxiety using claims data

2016. 01 – 2017. 08 **Systematic Literature Review and Cost analysis;** Cost-effectiveness of Alirocumab for hyperlipidemia in patients with high risk of cardiovascular events
Funding source: Sanofi-Aventis Korea

Role: Participating Researcher

- Conducted a systematic review to assess the effects of Alirocumab for hyperlipidemia in patients with high risk of cardiovascular events
- Analyzed Korean national claims database to estimate the costs required for cost-effectiveness analysis

2015. 01 – 2015. 09 **Systematic Literature Review;** Cost-effectiveness of Delamanid for multi-drug resistant tuberculosis

Funding source: Korea Otsuka Pharmaceuticals

Role: Participating Researcher

- Conducted a systematic review and Simple Comparison to assess the effects of Delamanid for multi-drug resistant tuberculosis

PUBLICATIONS

Peer-reviewed Articles, Published or In Press (underline denotes first author)

1. Sung-Hyun Hong, **Hye-Rim Kang**, Jin Hyun Nam, Sun-Kyeong Park, Tae-Bum Kim, Eui-Kyung Lee. A comparison of leukotriene receptor antagonists to low-dose inhaled corticosteroids in elderly mild asthmatics. J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2642-2652.e3.
2. **Hye-Rim Kang**, Sung-Hyun Hong, So-Young Yang, Tae-Bum Kim, Eui-Kyung Lee. Differences in the risk of mood disorders in patients with asthma-COPD overlap and in patients with COPD alone: a nationwide population-based retrospective cohort study in Korea. Respir Res. 2019 Apr 30;20(1):80.
3. **Hye-Rim Kang**, Ju Hwan Kim, Eui-Kyung Lee, Ju-Young Shin. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study—authors' response. J Antimicrob Chemother. 2019 Jun 1;74(6):1764-1765.

4. **Hye-Rim Kang**, Eui-Kyung Lee, Woo Jung Kim, Ju-Young Shin. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study. J Antimicrob Chemother. 2019 Feb 1;74(2):453-461.
5. **Hye-Rim Kang**, Hyun Jin Song, Jin Hyun Nam, Sung-Hyun Hong, So-Young Yang, SanEun Ju, Sang Won Lee, Tae-Bum Kim, Hye-Lin Kim, Eui-Kyung Lee. Risk factors of Asthma Exacerbation Based on Asthma Severity: A Nationwide Population-Based Observational Study in South Korea. BMJ Open. 2018;8:e020825.
6. Ji-Hye Byun, Jae-A Park, **Hye-Rim Kang**, Ju-Young Shin, Eui-Kyung Lee. Comparison of effectiveness between delamanid and bedaquiline among patients with multi-drug resistant tuberculosis: A Markov model simulation study. Clin Drug Investig. 2016 Nov;36(11):957-968.

Submitted (underline denotes the first author)

7. **Hye-Rim Kang**, Suk-Chan Jang, Ju-Young Shin. The risk of neuropsychiatric adverse events associated with the use of oseltamivir: a cohort study. Submitted to Expert Opinion on Drug Safety.
8. So-Young Yang, **Hye-Rim Kang**, Sun-Kyung Park, Eui-Kyung Lee, Sun-Hong Kwon. The difference in end-of-life care between patients with hematologic malignancies and solid tumor: a longitudinal data analysis. Submitted to BMJ Supportive & Palliative Care.
9. Hye-Lin Kim, Gi-Ae Kim, Jae-A Park, **Hye-Rim Kang**, Eui-Kyung Lee, Young-Suk Lim. Cost-effectiveness of Antiviral Treatment in Patients with Immune-Tolerant Phase Chronic Hepatitis B. Submitted to Gut.

Poster Presentations (Underline denotes the first author)

1. **Hye-Rim Kang**, Seongmin Joo, Eui-Kyung Lee. Associations of Depression and Anxiety with a Risk of Exacerbations in Asthma-Chronic Obstructive Pulmonary Disease Overlap. International Society for Pharmacoeconomics and Outcomes Research 21th European Congress; 2018 Nov 13; Barcelona, Spain
2. Hye-Lin Kim, Gi-Ae Kim, Jae-A Park, **Hye-Rim Kang**, Eui-Kyung Lee, Young-Suk Lim. Cost-Effectiveness of Anti-Viral Treatment in Patients with immune Tolerant-Phase Chronic Hepatitis B. APASL (Asian Pacific Association for the Study of the Liver) Single Topic Conference on Hepatitis B Virus; 2018 June 22-24; Taipei, Taiwan

3. **Hye-Rim Kang**, Eui-Kyung Lee, Woo Jung Kim, Ju-Young Shin. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study. 43rd Grand Congress Meeting of Korea Public Health Association; 2018 April 6; Seoul, South Korea
4. Sung-Hyun Hong, **Hye-Rim Kang**, Jin Hyun Nam, Tae-Bum Kim, Eui-Kyung Lee. Comparing the Risk of Asthma Exacerbation between Use of Inhaled Corticosteroids and Leukotriene Receptor Antagonists in the Elderly Patients with Asthma. International Society for Pharmacoeconomics and Outcomes Research 8th Asia Pacific; 2018 Sep 10; Tokyo, Japan
5. Jae-A Park, **Hye-Rim Kang**, Sung-Hyun Hong, Eui-Kyung Lee. Comparing Inhaled Corticosteroids and Long-Acting Beta Agonists Combination to Inhaled Corticosteroids on Risk of Ischemic Cardiovascular Diseases in Patients with Asthma. International Society for Pharmacoeconomics and Outcomes Research 20th European Congress; 2017 Nov 7; Glasgow, Scotland
6. Jieun Jang, **Hye-Rim Kang**, Hyemin Ku, Eui-Kyung Lee. Difference Patterns of the medical care utilization among heart failure patients in recent three years. Korean Academy of Social & Managed Care Pharmacy, Autumn Academic Conference; 2015 Nov 20; Korea.

HONORS & AWARDS

2016. 03 – 2019.02	Graduate Merit Scholarship Sungkyunkwan University, Korea
2018. 03 – 2019. 02	TA Scholarship Sungkyunkwan University, Korea
2015. 11	Poster Award 2015 Fall Korean Academy of Social & Managed Care Pharmacy Conference Seoul, Korea.
2013. 03 – 2016. 02	Kochon Scholarship ChonKunDang Pharmaceutical Corporation, Korea
2012. 03 – 2013. 02	Samsung Scholarship Sungkyunkwan University, Korea
2007. 03 – 2012. 02	National Scholarship for Science and Engineering Korea Student Aid Foundation (KOSAF), Korea

PROFESSIONAL ORGANIZATIONS

2018 – Present Korean Society of Epidemiology (KSE)

2018 – Present The Pharmaceutical Society of Korea (PSK)

2017 – Present Korean Association of Health Technology Assessment (KATHA)

2016 – Present International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

2016 – Present Korean Academy of Social and Managed Care Pharmacy (KASMCP)

EXPERIENCE WITH HEALTH-RELATED DATABASE

Claims data (Korea)

Health Insurance Review and Assessment Service (HIRA) database

Health Insurance Review and Assessment Service-National Patients Sample (HIRA-NPS)

Health Insurance Review and Assessment Service-National Inpatients Sample (HIRA-NIS)

National Health Insurance Service (NHIS) database

National Health Insurance Service-National Sample Cohort (NHIS-NSC)

Claims data linked to Electronic Medical Record (EMR)

HIRA database linked to EMR of Asan Medical Center in Korea

Registry data

Cohort for reality and evolution of adult asthma in Korea (COREA)

Panel data

Korea National Health and Nutrition Examination Survey (KNHANES)

SKILLS & OTHERS

Languages

English (intermediate conversational skills), Korean (native)

Technical Skills

SAS, TreeAge Pro Healthcare, Microsoft Excel, Review Manager (RevMan), ITC software provided by CADTH

Certifications & Training

2017. 09 TreeAge 2-day training and TreeAge Advanced Healthcare Modeling Course
 Sydney, Australia